ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 31 October 2008
Endocrine-Related Cancer (2008) In press
DOI: 10.1677/ERC-08-0142
Copyright © 2008 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dworakowska, D.
Right arrow Articles by Grossman, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dworakowska, D.
Right arrow Articles by Grossman, A.

REVIEW

Are neuroendocrine tumours a feature of tuberous sclerosis?

Dorota Dworakowska and Ashley Grossman

D Dworakowska, Centre for Endocrinology, Barts and the London School of Medicine, London, United Kingdom
A Grossman, Centre for Endocrinology, Barts and the London School of Medicine, London, United Kingdom

Correspondence: Ashley Grossman, Email: a.b.grossman{at}qmul.ac.uk

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder characterised by the development of multiple hamartomas in numerous organs. It is caused by mutations of two tumour suppressor genes, TSC1 on chromosome 9q34 and TSC2 on chromosome 16p13.3, which encode for hamartin and tuberin, respectively. The interaction between these two proteins, the tuberin-hamartin complex, has been shown to be critical to multiple intracellular signalling pathways, especially those in control of cell growth and proliferation. TSC may affect skin, central nervous system, kidneys, heart, eyes, blood vessels, lung, bone and gastrointestinal tract. Small series and case reports have documented that in tuberous sclerosis patients many endocrine system alterations might occur, affecting the function of the pituitary, parathyroid, and other neuroendocrine tissue. There have been scattered reports of the involvement of such tissue in the pathological process of TSC, but no systematic review as to whether this is a true association. We have therefore systematically assessed all available published literature in this area. We conclude that there may be an association with pituitary and parathyroid tumours, and two recent descriptions of Cushing's disease are especially intriguing. However, the evidence seems more firm in the case of islet cell, particularly insulinomas. As these latter may cause changes in mental state which may be confused with the cerebral manifestations of TSC per se, it is particularly important for physicians working with these patients to be aware of the putative and indeed likely association.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Endocrinology.